📰 Multiple Sclerosis Program News
Multiple Sclerosis Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple Sclerosis Program. Real-time updates on events, politics, business and more.
April 4, 2024
The professor is being recognized by the National Multiple Sclerosis Society and the American Academy of Neurology.
April 2, 2024
Dr. Rhonda Voskuhl, a professor of neurology at UCLA Health, has been awarded the 2024 John Dystel Prize for Multiple Sclerosis Research in recognition of her o
September 17, 2023
USA: A recent study published in The Lancet Neurology has revealed that an experimental method developed to detect nerve injury in multiple sclerosis (MS) in adults also works for children with MS and...
August 17, 2023
An experimental method developed to detect nerve injury in multiple sclerosis (MS) in adults also works for children with MS and other neurological conditions, even when they are symptom-free, according to an international team of researchers. In MS,
April 26, 2023
BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.“In the MS field, we need treatments that can better target both peripheral and centrally mediated inflammation, and I think there is a lot of hope for
September 6, 2022
I was lucky to land in the hands of a MS specialized neurologist from the get-go. This saved me time and ensured that my health was being overseen ...
June 8, 2022
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment.
April 5, 2022
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana
March 25, 2022
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022. NEW YORK, March 25, 2022) ("Tiziana"
March 25, 2022
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohns Disease, is anticipated to be completed by Q4, 2022.